High bioavailability of INM-901 oral formulation provides similar drug concentration levels in the brain as intraperitoneal (IP) injection VANCOUVER, BC – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM),… Read More
VANCOUVER, BC – WEX Pharmaceuticals Inc. (“WEX” or the “Company”), a clinical-stage biotechnology company developing Halneuron® (Tetrodotoxin for Injection) for pain, is pleased to announce the filing of a U.S…. Read More
Prioritization of screening programs for spinal muscular atrophy (SMA) will ensure early diagnosis across Canada and bring lasting impact to babies and caregivers MONTREAL – Novartis Pharmaceuticals Canada Inc. (Novartis) applauds the… Read More
RYBREVANT® plus LAZCLUZE™ is the first and only chemotherapy-free regimen showing superior progression-free survival versus osimertinib Following Priority Review, approval is based on Phase 3 MARIPOSA results showing RYBREVANT® plus LAZCLUZE™ reduced… Read More
A $2.5 million donation from the Conconi Family Foundation helped to unlock the federal grant. Together, government and philanthropic support has helped to launch the new Biodevice Foundry at SBME—a… Read More
